SDI-118, a novel procognitive SV2A modulator: First-in-human randomized controlled trial including PET/fMRI assessment of target engagement

• Main Authors: Wouter Botermans (Author), Michel Koole (Author), Koen Van Laere (Author), Jonathan R. Savidge (Author), John A. Kemp (Author), Stefan Sunaert (Author), Maeve M. Duffy (Author), Steven Ramael (Author), Andrea M. Cesura (Author), Kevin D'Ostilio (Author), Denis Gossen (Author), Torsten M. Madsen (Author), Thomas Lodeweyckx (Author), Jan de Hoon (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Current treatments for progressive neurodegenerative disorders characterized by cognitive impairment either have limited efficacy or are lacking altogether. SDI-118 is a small molecule which modulates the activity of synaptic vesicle glycoprotein 2A (SV2A) in the brain and shows cognitiv...